A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
A phase 3 trial of Durvalumab, Carboplatin, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Overview
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT03800134 by AstraZeneca, with 825 participants enrolled, started 2018-12-06 and due to reach its primary completion in 2022-11-10. Interventions recorded: Durvalumab, Placebo, Carboplatin, Cisplatin, Pemetrexed. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
Shares Pemetrexed, Durvalumab, Gemcitabine, Paclitaxel / nab-paclitaxel.
- TrialStudy of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
Shares Durvalumab, Gemcitabine, Paclitaxel / nab-paclitaxel, Cisplatin.
- TrialStudy of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
Shares Pemetrexed, Durvalumab, Gemcitabine, Cisplatin.
- TrialIPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Shares Pemetrexed, Durvalumab, Paclitaxel / nab-paclitaxel, Carboplatin.
- TrialA Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin.
- TrialA Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S
Shares Pemetrexed, Cisplatin, AstraZeneca, Carboplatin.
- TrialA Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, AstraZeneca.
- TrialVolrustomig Priming Regimens Exploratory Phase II Platform Study
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin.